Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation
Age and Ageing · 2026-08-03 · 55 (8)
DOI: 10.1093/ageing/afag246 ↗At a glance
Journal article in Age and Ageing, published online on 2026-08-19. Written by Hisashi Noma and 6 co-authors. Institution: Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. 45 references.
Abstract (original language)
Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes, but evidence in adults aged ≥75 years remains limited, particularly compared with dipeptidyl peptidase-4 inhibitors (DPP-4i).
Methods
We conducted a target trial emulation using linked administrative claims and health examination data in Japan. Individuals aged ≥75 years with type 2 diabetes who newly initiated an SGLT2i or DPP-4i were identified. Intention-to-treat (ITT) effects were estimated using inverse probability weighting, with a 1-month induction period for mortality, cardiovascular and renal outcomes.
Results
The study included 8486 individuals (2204 SGLT2i users, 6282 DPP-4i users). After a 1-month induction period, SGLT2i initiation was associated with lower all-cause mortality (hazard ratio [HR] 0.677, 95% confidence interval [CI] 0.500–0.916) and lower risk of end-stage renal disease or dialysis (HR 0.374, 95% CI 0.157–0.890). No clear differences were observed for heart failure hospitalisation (HR 1.103, 95% CI 0.854–1.426) or myocardial infarction (HR 1.015, 95% CI 0.768–1.341) in the ITT analysis. Stroke occurred more frequently among SGLT2i users (HR 1.420, 95% CI 1.165–1.828), although this finding should be interpreted cautiously.
Conclusions
Among adults aged ≥75 years with type 2 diabetes, SGLT2i initiation was associated with lower all-cause mortality and renal risk compared with DPP-4i initiation. The higher observed stroke risk requires cautious interpretation because residual confounding, competing mortality and heterogeneity in vulnerable older adults may contribute to this signal.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan.
- The Graduate Institute for Advanced Studies, The Graduate University for Advanced Studies (SOKENDAI), Tachikawa, Tokyo, Japan.
- Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Yonago, Tottori, Japan.
- Department of Public Health, School of Medicine, Association of Medical Science, Yokohama City University, Yokohama, Kanagawa, Japan.
- Department of Prevention and Care Science, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
- Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
ORCID profiles: Hisashi Noma, Atsushi Goto, Taiki Sugimoto
Cite
APA
Noma, H., Goto, A., Sugimoto, T., Sunada, H., Oda, F., Maeda, M., & Fukuda, H. (2026). Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag246
Vancouver
Noma H, Goto A, Sugimoto T, Sunada H, Oda F, Maeda M, et al. Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag246
BibTeX
@article{Noma2026,
author = {Noma, Hisashi and Goto, Atsushi and Sugimoto, Taiki and Sunada, Hiroshi and Oda, Futoshi and Maeda, Megumi and Fukuda, Haruhisa},
title = {Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {8},
doi = {10.1093/ageing/afag246}
}
EUVIMED